Our Focus: The Maternal-Infant Axis

The gut microbiome plays a critical role in immune maturation and healthy development in the first years of life. Disruption of the microbiome, known as dysbiosis, leads to a multitude of diseases with life-long impacts.  Leveraging this unique window of opportunity, Siolta is developing novel live biotherapeutic products designed to prevent and/or treat diseases in the “maternal-infant axis”.

 

 

The human microbiome plays a critical role in human health. Human clinical data suggests that the dysbiosis (the imbalance of microbial communities) of the microbiome can lead to the onset or recurrence of a wide range of diseases including allergic disease, bacterial vaginosis (BV) and necrotizing enterocolitis (NEC).  Our expertise in the infant gut microbiome has led to the development of STMC-103H for the prevention of atopic diseases in newborns. Given the strong scientific rationale supporting the use of microbiome-based therapeutics, we have initiated two new multi-strain preclinical programs designed to prevent the recurrence of BV in women and to prevent the onset of NEC, a rare pediatric disease, in preterm infants.

  • Atopic Diseases
  • Bacterial Vaginosis (BV)
  • Necrotizing Enterocolitis

Atopic Diseases

Atopic diseases including atopic dermatitis, food allergy, and allergic asthma represent a global health problem that disproportionately impacts children.  Surprisingly,  there are no approved approaches to prevent the development of these diseases in at-risk individuals, resulting in chronic morbidity and economic burden.  There is a crucial need to develop innovative strategies to prevent the onset of these Type 1 allergic diseases rather than treating their symptoms.  A  preventative approach targeting at-risk individuals could significantly reduce the morbidity and healthcare burden associated with these increasingly common conditions.

Impact and Opportunity
$80B
Annual direct cost of atopic diseases in the US 1
2 FDA Options
Injectable Mab and a topical DP4 are the only FDA approved options 2

Allergic Disease

 

The prevalence of atopic diseases has increased dramatically during recent decades, especially in industrialized nations.

>20M
Children and adolescents diagnosed with atopic disease in the USA 3
12-30%
Newborns at risk of developing atopic diseases 4

At Siolta Therapeutics we are leveraging our knowledge of the human microbiota’s impact on adaptive immune responses to develop novel live biotherapeutic products (LBPs) aimed at preventing and treating diseases with unmet medical needs. By applying our Precision Symbiotics Platform™, we develop LBPs composed of bacterial consortia to address the metabolic and immunological origins of disease. We pride ourselves on being one of the first microbiome medicines companies to move a mixed-species LBP into clinical development in the US.

See our Pipeline